|
Match
|
Document |
Document Title |
|
|
US20090275614 |
Methylphenidate Derivatives and Uses of Them
The present invention provides methods of using compounds of formula I:
and salts and prodrugs thereof, wherein n, R 1 and R 2 are defined herein. The invention also provides certain novel...
|
|
|
US20090264465 |
CRYSTALLINE FORMS OF 4- [2- (4-METHYLPHENYLSULFANYL) -PHENYL] PIPERIDINE WITH COMBINED SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITION FOR THE TREATMENT OF NEUROPATHIC PAIN
Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine and salts thereof are provided e.g. for the treatment of neuropathic pain.
|
|
|
US20090258901 |
LIGANDS FOR MONOAMINE RECEPTORS AND TRANSPORTERS, AND METHODS OF USE THEREOF
One aspect of the present invention relates to heterocyclic compounds. A second aspect of the present invention relates to the use of the heterocyclic compounds as ligands for various mammalian...
|
|
|
US20090253743 |
COMPOSITIONS OF TOLPERISONE
The present disclosure is directed to methods for providing tolperisone having extremely low levels of 4-MMPPO (2-methyl-1-(4-methylphenyl)-propenone), as well as related compositions. The...
|
|
|
US20090247581 |
Organic Compounds
The present invention relates to a process for the synthesis of (S)-2′[2-1-(methyl-2-piperidyl) ethyl] cinnamanilide (I) or salts or pharmaceutically acceptable prodrugs thereof:
|
|
|
US20090246145 |
Imaging Correlates of Neurogenesis With MRI
This invention provides a method for treating a mammalian subject afflicted with a disorder associated with reduced neurogenesis in the subject's hippocampal dentate gyrus which comprises...
|
|
|
US20090215820 |
NOVEL ALKYL SUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS
This invention relates to novel alkyl substituted piperidine derivatives useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these...
|
|
|
US20090214680 |
Weight Loss Composition
The present invention comprises a purposefully formulated weight loss composition and a method for causing a meaningful weight loss in a living human subject. The formulated weight loss...
|
|
|
US20090209525 |
ENABLING METHODS TO IDENTIFY ALLOSTERIC MODULATORS OF RECEPTOR ACTIVITY
A method developed to identify receptor modulators, involving providing a mutant receptor, wherein said mutant receptor has a mutation that alters the activity of said mutant receptor compared to a...
|
|
|
US20090209461 |
MODIFICATION OF FEEDING BEHAVIOR
Methods are disclosed for decreasing calorie intake, food intake, and appetite in a subject. The methods include peripherally administering a therapeutically effective amount of PYY or an agonist...
|
|
|
US20090202439 |
Methods for treatment of angiogenesis
The present invention includes methods for treatment and prophylaxis of diseases, post-surgical disorders and bacterial infections associated with lactosylceramide. The methods generally provide...
|
|
|
US20090197823 |
ALISKIREN MODULATION OF NEUROGENESIS
The disclosure provides compositions and methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis by use of a renin...
|
|
|
US20090186919 |
PIPERIDINE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE
Compounds of formula (I) modulate the activity of gamma secretase and hence find use in treatment or prevention of Alzheimer's disease and related conditions.
|
|
|
US20090181850 |
LOW ODOR, LOW VOLATILITY SOLVENT FOR AGRICULTURAL CHEMICALS
A composition includes an agricultural component in an amount of at least about 27% by weight and a solvent composition in an amount not greater than about 55% by weight. The solvent composition...
|
|
|
US20090170841 |
Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders
The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are...
|
|
|
US20090163461 |
Ligand for Vesicular Acetylcholine Transporter
The present invention provides a novel compound represented by the formula (I):
wherein R 1 and R 2 are as defined in the specification, or a salt thereof, which is useful as a reagent...
|
|
|
US20090163451 |
METHODS FOR TREATING VISCERAL PAIN
The invention features methods of treating visceral pain in humans by administering an effective amount of a 5HT 1B or 5HT 1D receptor agonist, (e.g., a triptan). These methods can be used, for...
|
|
|
US20090155389 |
Selective serotonin receptor inverse agonists as therapeutics for disease
Disclosed herein are pharmaceutical compositions comprising an inverse serotonin receptor agonist or a serotonin receptor antagonist and an anti-psychotic agent. Disclosed herein are also methods...
|
|
|
US20090149497 |
POLYMORPHS OF FEXOFENADINE HYDROCHLORIDE
The present invention provides novel crystal forms of fexofenadine hydrochloride Forms V, VI and VIII through XV and processes for their preparation and preparation of amorphous form and other...
|
|
|
US20090149446 |
Compositions Comprising Nicotinic Agonists and Methods of Using Same
The disclosure is directed at least in part to compositions and methods comprising nicotinic agonists for treating e.g., nervous system disorders, in particular, to combination therapies that...
|
|
|
US20090143397 |
CATECHOL-BASED DERIVATIVES FOR TREATING OR PREVENTING DIABETICS
The present invention provides a catechol-based derivative and a pharmaceutical acceptable salt therefrom and a solvate therefrom. A pharmaceutical composition for preventing or treating diabetics...
|
|
|
US20090142301 |
NOVEL PHARMACEUTICAL COMPOSITION OF INTERFERON GAMMA OR PIRFENIDONE WITH MOLECULAR DIAGNOSTICS FOR THE IMPROVED TREATMENT OF INTERSTITIAL LUNG DISEASES
The present invention relates to a novel pharmaceutical composition of compounds having the biological activity of interferon gamma (IFN-γ) or pirfenidone in combination with a diagnostic array of...
|
|
|
US20090131441 |
Metabolites Of 2-Arylpropionic Acid Derivatives And Pharmaceutical Compositions Containing Them
Metabolites of 2-(R)-4-isobutylarylpropionamides and pharmaceutical compositions containing such compounds are useful in inhibiting the chemotactic activation of neutrophils (PMN leukocytes)...
|
|
|
US20090124659 |
Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase and inhibitors
The invention relates to a novel drug combination therapy useful in the treatment of dementia comprising administering an 1-aminocyclohexane derivative such as memantine or neramexane and an...
|
|
|
US20090124592 |
PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING A PATHOLOGY ASSOCIATED WITH AN OBSESSIONAL BEHAVIOR OR WITH OBESITY
This invention relates to the use of a ligand of the 5-HT 4 receptor or of a pharmaceutically acceptable salt of this ligand and to a nucleic acid coding for a 5-HT 4 receptor or of a...
|
|
|
US20090118331 |
Use of Lobeline Epimers in the Treatment of Central Nervous System Diseases, Pathologies, and Drug Abuse
Methods of delivering or administering stabilized formulations or compositions having predetermined ratios, or range of ratios, of constituent epimers to an individual or a mammal for treatment of...
|
|
|
US20090118257 |
4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, and...
|
|
|
US20090117167 |
Injectable capsaicin with vasocontrictor adjunctive agent
Disclosed in certain embodiments is a method for relieving pain at a site in a human or animal in need thereof, comprising administering by injection or infiltration, a dose of a capsaicinoid and...
|
|
|
US20090111853 |
FEXOFENADINE POLYMORPHS AND PROCESS FOR THE PREPARATION THEREOF
The invention provides novel crystalline forms of fexofenadine hydrochloride, a process for the preparation of the novel forms and of the known form A, and their use in therapy.
|
|
|
US20090111808 |
NOVEL HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS
The present patent application concerns compounds of formula (I) with R1 and R2 taken together with the nitrogen atom to which they are attached, form a mono or bicyclic saturated...
|
|
|
US20090110728 |
Zero-Order Modified Release Solid Dosage Forms
The invention comprises a solid dosage form for delivery of water soluble pharmaceutical agents. The solid dosage form comprises a matrix core containing the pharmaceutical agent and a hydrophobic...
|
|
|
US20090105275 |
PIPERIDINYL AND PIPERAZINYL MODULATORS OF y-SECRETASE
The present invention relates to compounds of Formula I as shown below, wherein the definitions of Het, R 0 , R 1 R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are provided in the...
|
|
|
US20090105260 |
Molecules to Enhance Percutaneous Delivery and Methods for Discovery Therefor
An IR spectroscopic technique provides methods for measuring the irritation potential of a formulation and to assess the ability of molecules to enhance the permeability of substances into and...
|
|
|
US20090099154 |
Pharmaceutical Sustained Release Compositions and Processes Thereof
Pharmaceutical sustained release composition comprising at least one active agent(s), or its tautomeric forms, analogues, isomers, polymorphs, solvates, or salts thereof; preferably an antiviral...
|
|
|
US20090088455 |
Chronic, Bolus Adminstration Of D-Threo Methylphenidate
Chronic bolus administration of D-threo methylphenidate is provided. The administration of the D-threo isomer eliminates adverse side effects associated with the DL racemate, and provides improved...
|
|
|
US20090082398 |
CRYSTALLINE FORMS OF FEXOFENADINE HYDROCHLORIDE AND PROCESSES FOR THEIR PREPARATION
Provided are crystalline forms of fexofenadine hydrochloride and processes for their preparation.
|
|
|
US20090076080 |
DEUTERIUM-ENRICHED FEXOFENADINE
The present application describes deuterium-enriched fexofenadine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
|
|
|
US20090076079 |
DEUTERIUM-ENRICHED METHYLPHENIDATE
The present application describes deuterium-enriched methylphenidate, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
|
|
|
US20090076019 |
METHODS FOR TREATING NEUROLOGICAL DISORDERS OR DAMAGE
A clonogenic neurosphere assay is described that carries out high throughput screens (HTS) to identify potent and/or selective modulators of proliferation, differentiation and/or renewal of neural...
|
|
|
US20090075993 |
Pharmaceutically effective compounds
The subject invention relates to carboxamidine derivatives, to pharmaceutical compositions comprising the same, and the use thereof in the preparation of pharmaceutical compositions for the...
|
|
|
US20090062341 |
Nuclear receptor binding agents
The present invention relates to a novel class of selective estrogen receptor modulators (SERMs). The SERM compounds are applicable for use in the prevention and/or treatment of a variety of...
|
|
|
US20090062340 |
NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE PPARY TYPE RECEPTORS AND COSMETIC/PHARMACEUTICAL COMPOSITIONS COMPRISED THEREOF
Novel biaromatic compounds having the structural formula (I) below:
are formulated into pharmaceutical compositions suited for administration in human or veterinary medicine (in dermatology, and...
|
|
|
US20090062336 |
Methods of Diminishing Co-Abuse Potential
Methods of diminishing or eliminating the co-abuse of a methylphenidate drug comprising identifying a patient or patient group suspected or likely to abuse said methylphenidate drug in combination...
|
|
|
US20090062260 |
COMPOUNDS AND COMPOSITIONS AS LXR MODULATORS
The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of...
|
|
|
US20090062242 |
METHODS AND COMPOSITIONS FOR TREATING GASTROINTESTINAL CONDITIONS
Methods and compositions for treating a condition involving gastrointestinal symptoms comprising administering to a patient in need of such treatment an effective amount of a P-glycoprotein...
|
|
|
US20090054486 |
POLYMORPHIC FORM XVI OF FEXOFENADINE HYDROCHLORIDE
Provided is a crystalline (polymorphic) form of fexofenadine hydrochloride, denominated fexofenadine hydrochloride Form XVI.
|
|
|
US20090054435 |
Phenoxyalkanoic Acid Compound
The present invention provides a compound represented by the formula:
wherein each symbol is as defined in the specification. Since the compound of the present invention has superior...
|
|
|
US20090053310 |
NOVEL SUSTAINED RELEASE DOSAGE FORM
The novel sustained release dosage form comprising an active agent and a combination of a non-swelling pH dependent release retardant and a non swelling pH independent release retardant polymer...
|
|
|
US20090048257 |
COMPOUNDS THAT MODULATE PPAR ACTIVITY, THEIR PREPARATION AND USE
Novel compounds of the general formula (I), the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these...
|
|
|
US20090048234 |
Pharmaceutical compositions and methods for preventing, treating, or reversing neuronal dysfunction
The present invention provides compositions and methods for preventing, treating or reversing neuronal dysfunction in a mammal resulting from exposure to organophosphate nerve agents,...
|